Cited 3 times in
Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박유랑 | - |
dc.contributor.author | 이유미 | - |
dc.contributor.author | 이민영 | - |
dc.date.accessioned | 2023-03-22T02:02:46Z | - |
dc.date.available | 2023-03-22T02:02:46Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 0026-0495 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193510 | - |
dc.description.abstract | Aims/hypothesis: Immune checkpoint inhibitor (ICI) has been emerged as a promising cancer treatment. However, ICI use induces immune-related adverse events, including diabetes mellitus. We compared the risk of new-onset diabetes between patients receiving an ICI and those receiving conventional chemotherapy (CC). Methods: Using a tertiary care hospital database, we included cancer patients without a previous history of diabetes who were treated with either CC or an ICI. One-to-five nearest neighbor propensity matching was applied, and the risk of diabetes was estimated using a Cox proportional hazards model. Latent class growth modeling was performed with a trajectory approach to determine distinct clusters that followed similar glucose trajectory patterns over time. Results: Among 1326 subjects, 1105 received CC, and 221 received an ICI. The risk of new-onset diabetes was significantly higher in the ICI group than the CC group (adjusted hazard ratio 2.454, 95 % confidence interval 1.528-3.940; p < 0.001). The ICI group had a higher proportion of subjects in the trajectory cluster with an increasing glucose pattern than the CC group (10.4 % and 7.4 %, respectively). Within the ICI group, the subjects with an increasing glucose pattern were predominantly male and associated with enhanced lymphocytosis after ICI administration. Conclusions: ICI therapy is associated with an increased risk of incident diabetes compared with CC. The glucose levels of patients treated with an ICI, especially males and those with prominent lymphocytosis after ICI treatment, need to be monitored regularly to detect ICI-associated diabetes as early as possible. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | W.B. Saunders | - |
dc.relation.isPartOf | METABOLISM-CLINICAL AND EXPERIMENTAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Diabetes Mellitus* / chemically induced | - |
dc.subject.MESH | Diabetes Mellitus* / epidemiology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glucose | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immune Checkpoint Inhibitors / adverse effects | - |
dc.subject.MESH | Lymphocytosis* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tertiary Care Centers | - |
dc.title | Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) | - |
dc.contributor.googleauthor | Minyoung Lee | - |
dc.contributor.googleauthor | Kyeongseob Jeong | - |
dc.contributor.googleauthor | Yu Rang Park | - |
dc.contributor.googleauthor | Yumie Rhee | - |
dc.identifier.doi | 10.1016/j.metabol.2022.155311 | - |
dc.contributor.localId | A05624 | - |
dc.contributor.localId | A03012 | - |
dc.relation.journalcode | J02223 | - |
dc.identifier.eissn | 1532-8600 | - |
dc.identifier.pmid | 36122764 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0026049522001895 | - |
dc.subject.keyword | Diabetes mellitus | - |
dc.subject.keyword | Immune checkpoint inhibitor | - |
dc.subject.keyword | Trajectory analysis | - |
dc.contributor.alternativeName | Park, Yu Rang | - |
dc.contributor.affiliatedAuthor | 박유랑 | - |
dc.contributor.affiliatedAuthor | 이유미 | - |
dc.citation.volume | 138 | - |
dc.citation.startPage | 155311 | - |
dc.identifier.bibliographicCitation | METABOLISM-CLINICAL AND EXPERIMENTAL, Vol.138 : 155311, 2023-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.